Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma

Abstract

This study showed that long-term therapy with omalizumab for up to 3 years was well tolerated with significant improvement both in symptoms and lung functions. Accordingly, long-term omalizumab treatment may be recommended for responders.

Omalizumab Treatment in Patients with Severe Allergic Asthma

“…In terms of efficacy, our findings were consistent with literature (10)(11)(12)(13)(14). While only 11.1% of our patients did not benefit from the treatment, 88.9% were benefited.…”

“…However, the asthma control test scores of the patients were found to increase at a rate of 94% with omalizumab treatment. In a study by Özgür et al (14), in 26 asthmatic patients treated with omalizumab, the duration of omalizumab treatment was 40.81±8.2 months and an improvement was also detected in FEV1 and in asthma control test scores of all patients compared to the baseline values. In addition, there was a significant decrease (p<0.05) in the number of attacks of the patients, emergency service applications, and the use of systemic glucocorticoids and short-acting beta2-agonists at the end of 36 months; the life quality of patients was also improved.…”

“…In earlier studies and reviews, omalizumab treatment has proven to be effective and safe in severe allergic asthmatic cases (10)(11)(12). However, there were few studies on this subject in Turkey (13,14). In a real-world study conducted by Bavbek et al (13), the evaluations of 18 patients 1 year before treatment were compared with their conditions when they were included into the study.…”

Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial

“…The optimal duration of omalizumab treatment has not been clearly identified [34, 35]. However, a previous study emphasized the need for long-term use for the potential effects to develop and a need for relevant data [19]. We therefore believe our results will provide an important reference regarding this approach.…”

“…The increase has been reported to be maintained at year 4 as 19% [24, 33]. Although the reason for the difference between FEV 1 results reported from real-life studies and RCTs is not clear, one study emphasized the need for longer treatment to ensure an FEV 1 increase [19] but this has not yet been clarified.…”